Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FDA Endocrinology Division To Be Led By Thanh Hai On Interim Basis; Guettier Leaving For Private Sector

Executive Summary

Mary Thanh Hai ran the US agency's division for seven years before moving up in 2013; Guettier’s departure may provide an opportunity for CDER Director Woodcock to start to implement her vision for changes in the Office of New Drugs.

Advertisement

Related Content

US Office Of New Drugs Revamp Taking Shape: More Review Divisions Coming, But Who Will Lead Them?
More US FDA Departures: ODE II Director Rosebraugh, GI Division Director Griebel to Retire
FDA Pulmonary/Rheumatology Division Sees Management Shakeup
Sanofi's Admelog, a Humalog Follow-On, Approved In US As 'Black Hole' For Insulins Looms
Patient Input Comes Full Circle: Ex-FDAer Gives Feedback To FDA

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

PS122114

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel